At The Reginald and Dionne Smith Foundation, Inc. (RDSF) we believe that education is a “right” for those infected and affected by illnesses such as HIV/AIDS and viral Hepatitis. We recognize that education forms the very essence of how successful we all are at overcoming illnesses, because how we respond is influenced greatly by what we know and have learned, either through instructions, observation, or assimilation. As individuals dedicated to extending and improving the lives of those with illnesses such as HIV/AIDS and viral Hepatitis, we accept the responsibility of helping to provide useful education to men and women living with the diseases, their partners, family members, and advocates.


    Rate four times the national average in this population By Molly Walker, Staff Writer, MedPage Today May 08, 2017 SAN DIEGO — Women living with HIV had a lifetime prevalence of post-traumatic stress disorder four times the national average, according to a small study examining women from an urban HIV… Read more »

    First generic version of Truvada approved for pre-exposure prophylaxis By MedPage Today Staff June 09, 2017 Individuals at risk for contracting HIV can now access a generic version of emtricitabine and tenofovir disoproxil fumarate, known as Truvada in branded form, that can be used to prevent infection, the FDA announced…. Read more »

    By Mike Bassett, Contributing Writer, MedPage Today May 18, 2017 BOSTON — Antiretroviral therapies may not be as effective at eliminating HIV from semen as they are in eliminating it from blood, researchers reported here. In an analysis of semen samples from more than 200 HIV-positive men, a significant proportion… Read more »

    Program aimed at addressing age-related disparities in HIV care By Molly Walker, Staff Writer, MedPage Today May 22, 2017   Around three-quarters of HIV-positive youth were linked with healthcare resources within six weeks of the implementation of a national strategy to improve HIV care in this population, researchers found. Programs… Read more »

    May 3, 2017 The nonprofit organization International Partnership for Microbicides, or IPM, recently announced the launch of a phase 1 trial assessing the safety and efficacy of its 3-month vaginal ring designed to prevent HIV and unintended pregnancy. According to a press release, the multipurpose ring slowly and simultaneously releases… Read more »

    Published on Wednesday, 15 February 2017 Written by Liz Highleyman  Sustained viral suppression over the course of a year may be a better measure than the most recent viral load test result when it comes to understanding access to and engagement in HIV care, according a study by Centers for… Read more »

    Published on Monday, 20 February 2017 Written by Liz Highleyman Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a Phase 3 clinical trial of people starting antiretroviral therapy (ART) for the first time, but it had a… Read more »

    Molecule could be first step to eradicating virus ‘reservoir’ By: Michael Smith North American Correspondent, MedPage Today March 16, 2017   For the first time, investigators have found a biomarker that identifies some cells latently infected with HIV. The molecule, dubbed CD32a, is found on the surface of about half… Read more »

    Liz Highleyman Produced in collaboration with Published: 24 June 2016 More than 49,000 people in the US have filled prescriptions for Truvada for pre-exposure prophylaxis (PrEP) at retail pharmacies, according to the results of a survey by Gilead Sciences presented this week at the ASM Microbe conference in Boston…. Read more »

    Faced with time and distance barriers along with enduring social bias, HIV-positive rural dwellers are less likely to find a clinic near their homes, more apt to drop out of care and more vulnerable to pervasive stigma where they live and work, experts said at a recent webcast. Reports of… Read more »

    Test can be run using very small blood sample by Greg von Portz and Satish Misra, MD December 14, 2016 British researchers at Imperial College London and hardware developers DNA Electronics have created a way to test for HIV using a USB stick plugged into a computer that analyzes a… Read more »

    On World AIDS Day there is much to celebrate by Michael Smith North American Correspondent, MedPage Today December 01, 2016   When the first World AIDS Day was marked, on Dec. 1, 1988, only one drug — zidovudine (AZT) — had been approved to treat HIV. And it was already… Read more »

    Baeten JM, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1506110. December 8, 2016 Women with a monthly vaginal ring containing dapivirine had a reduced risk for HIV-1 infection compared with those with a placebo; in addition, efficacy was increased among women who had higher rates of adherence, according to findings published… Read more »

    December 20, 2016 The primary endpoint of noninferiority was met in two phase 3 trials evaluating the safety and efficacy of switching virologically suppressed patients with HIV from a three- or four-drug ART regimen to a two-drug regimen containing Tivicay and Edurant, according to ViiV Healthcare. The investigational regimen of… Read more »

    By Warren Tong From December 7, 2016   Charlie Sheen Charlie Sheen (Credit: Angela George [CC BY-SA 3.0], via Wikimedia Commons) Actor Charlie Sheen revealed this month that he has achieved an undetectable viral load by taking PRO 140, an injectable HIV drug that’s currently being studied, according to… Read more »

    By Michael Broder, PhD Reviewed by Mark Wainberg, PhD, Director, McGill University AIDS Centre, Montreal, Quebec, Canada Take Note Estimates are that more than 50% of people living with HIV in the United States are now aged 50 or older Older patients with HIV are affected by typical age-related chronic… Read more »

    Everyday battle for Braintree man Lindsay Kalter Tuesday, November 22, 2016 Credit: Lisa Hornak DIAGNOSED IN 1985: Adam Barrett, 55, of Braintree, above, has been living with HIV for over 30 years and credits his progress to the work of researchers such as AIDS Clinical Trials Group Network Principal Investigator… Read more »

    November 15, 2016 Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class. The remarkable breadth and potency of this antibody, named N6,… Read more »

    MAGGIE FOX, NBC News Oct 27th 2016 6:45AM A new genetic study confirms theories that the global epidemic of HIV and AIDS started in New York around 1970, and it also clears the name of a gay flight attendant long vilified as being “Patient Zero.” Researchers got hold of frozen… Read more »

    A look at the benefits of antiretroviral therapy and recommendations BY DR. CHRIS M. NGUYEN Without HIV medications, known as antiretroviral therapy (ART), most people living with HIV will go on to develop severe depletion of their CD4 (T cells), leading to AIDS-related illnesses and premature death. The recommendations on… Read more »

    By Carlos del Rio, MD, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in New York, New York, in March 2016 The HIV epidemic in the United States disproportionately affects populations that have historically suffered from health disparities. Thus, addressing HIV prevention and care requires… Read more »

     Written by: The Panel on Antiretroviral Guidelines for Adults and Adolescents   Panel’s Recommendations Regarding Initial Combination Regimens for the Antiretroviral-Naive Patient An antiretroviral (ARV) regimen for a treatment-naive patient generally consists of two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third active ARV drug from one of… Read more »

    For decades HIV-positive patients were barred from organ donation, but recent policy changes have seen that federal ban reversed. Now surgeons at transplant centers that meet specific requirements including involvement in clinical research can implant organs from HIV-positive patients. The National Institutes of Health (NIH) is planning a new study… Read more »

    By Michael Smith North American Correspondent, MedPage Today Action Points: Efficacy maintained although condom use fell Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. On-demand pre-exposure prophylaxis (PrEP) against… Read more »


    Glecaprevir/pibrentasvir highly effective against most hepatitis C genotypes By Liz Highleyman, Contributing Writer, MedPage Today April 20, 2017 AMSTERDAM — An investigational combination of two antiviral agents taken for three months cured almost all patients with compensated liver cirrhosis and hepatitis C virus (HCV) genotypes 1, 2, 4, 5, or… Read more »

    Formulation now recommended in updated HBV treatment guidelines By Liz Highleyman, Contributing Writer, MedPage Today April 24, 2017 AMSTERDAM — Hepatitis B patients who switched to a new formulation of tenofovir showed improvements in bone and kidney safety in a pair of long-running studies, researchers reported here. Tenofovir alafenamide (TAF,… Read more »

    By: Gerard Gallagher January 25, 2017 Researchers raised questions about the long-term safety of direct-acting antivirals for hepatitis C virus infection after an analysis of FDA data uncovered more than 500 reports of liver failure and more than 1,000 reports of severe liver injury related to the drugs over one… Read more »

    Lasser KE et al. Ann Fam Med. 2017;doi:10.1370/afm.2069. May 11, 2017 By Janel Miller A hepatitis C treatment program at an urban safety-net hospital that utilized a public health social worker, general internists trained in hepatitis C treatment, pharmacists, and pharmacy technicians led to nearly one out of every four… Read more »

    By Michael Smith North American Correspondent, MedPage Today April 21, 2017 AMSTERDAM — As a global health threat, viral hepatitis has annual mortality on a par with tuberculosis and HIV, according to a new report from the World Health Organization. The difference is that mortality for HIV and TB has… Read more »

    March 13, 2017 Millions of Americans have been infected with the Hepatitis C virus – but only a portion progress to severe liver damage. Clinicians discuss many reasons contributing to Hepatitis C-induced liver damage. New research now includes a genetic variant on the list of liver damage offenders.   There… Read more »

    ACS study finds slight increase in wake of screening recommendation By:  Michael Smith North American Correspondent, MedPage Today March 08, 2017   More baby boomers had been tested for hepatitis C (HCV) two years after a recommendation for universal one-time testing — but not many more, researchers reported.   The… Read more »

    The National Viral Hepatitis Action Plan 2017-2020 (Action Plan) is our nation’s battle plan for fighting s viral hepatitis in the United States. The updated plan outlines strategies to achieve four major goals and includes indicators to help track progress between now and 2020. The goals are: Goal 1: Prevent… Read more »

    HIV and Hepatitis Article January 29, 2016 Merck announced the FDA has approved Zepatier for the treatment of adult patients with chronic hepatitis C virus genotype 1 and 4 infection, with or without ribavirin. Zepatier (grazoprevir/elbasvir, Merck), a once-daily, fixed-dose combination tablet containing 50 mg of elbasvir, an NS5A inhibitor,… Read more »

    August 9, 2016 Patients with hepatitis C who were also being treated for opioid addiction achieved high rates of sustained virologic response with Zepatier, according to data published in the Annals of Internal Medicine. Gregory J. Dore, MD, head of the Viral Hepatitis Clinical Research Program at the Kirby Institute… Read more »

    By DENISE GRADY JAN. 24, 2017 The New York Times   Drugs approved in recent years that can cure hepatitis C may have severe side effects, including liver failure, a new report suggests. The number of adverse events appears relatively small, and the findings are not conclusive. But experts said… Read more »

    Published on Monday, 21 November 2016 Written by Liz Highleyman   More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C — including many with liver cirrhosis — achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce… Read more »

    December 1, 2016 By: Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Corinna Dan, R.N., M.P.H., Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services Summary: December 1st is World… Read more »

    Vemlidy approved for chronic HBV infection with compensated liver disease by John Gever Managing Editor, MedPage TodayNovember 10, 2016 The FDA has approved tenofovir alafenamide (TAF), to be sold as Vemlidy, for adults with chronic hepatitis B infection with compensated liver disease, said manufacturer Gilead Sciences on Thursday. TAF is a prodrug… Read more »

    November 11, 2016 The FDA approved Vemlidy at 25 mg for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease, according to a press release from the manufacturer. Vemlidy (tenofovir alafenamide, Gilead Sciences; TAF) — a nucleoside analog reverse transcriptase inhibitor — is a prodrug… Read more »

    Ingiliz p, et al. J Hepatol. 2016;doi:10.1016/j.jhep.2016.09.004. October 31, 2016 In a retrospective study, researchers found that hepatitis C virus reinfection is common among HIV-positive men who have sex with men after successful treatment and spontaneous clearance. A subsequent high incidence of HCV reinfection has been reported regionally in men… Read more »

    Published on Wednesday, 05 October 2016 00:00 Written by Liz HIghleyman The U.S. Food and Drug Administration (FDA) this week issued a new safety warning about the risk of hepatitis B virus (HBV) reactivation in people treated with direct-acting antivirals (DAAs) for hepatitis C. In a few cases HBV reactivation… Read more »

    Published on Thursday, 29 September 2016 Written by Liz HIghleyman People considering treatment for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as successful elimination of hepatitis C virus (HCV) can reactivate HBV and potentially worsen liver disease, according to recent updates to… Read more »

    By Molly Walker; Staff Writer, MedPage Today   7/22/16 The birth rate among women with hepatitis C virus (HCV) infection is increasing nationally, though the problem is particularly prevalent in Kentucky, CDC researchers reported. Nationally, the number of infants born to women testing positive for HCV rose 68% — from 0.19%… Read more »

    On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 — the first approved oral pangenotypic regimen. While it is more effective against… Read more »

    Written by Liz Highleyman Hepatitis B and C have become leading causes of death and disability worldwide, as other major communicable diseases such as HIV/AIDS, malaria, and tuberculosis (TB) have come under better control, according to an analysis published in the July 8 online edition of The Lancet. Experts estimate… Read more »